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Abstract 
Review on MKI67, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: KIA, MIB-1 
HGNC (Hugo): MKI67 
Location: 10q26.2 
Local order 
CLRN3, PTPRE, MKI67, LINC01163, MGMT. 
Note 
MKI67 is the human homologue of the product 
recognized by the monoclonal antibody Ki67, 
which is used as a tumor proliferation marker. 
DNA/RNA 
Note 
MKI67 is located on chromosome 10 at locus  
10q26.2, starting at 128096659 and ending at 
128126204 bp from pter (according to GRCh38 
Primary Assembly). The gene size is 29,545 bp 
consisting of 15 exons and 14 introns. The gene has 
a minus strand orientation. 
Description 
Promoter: The promoter of MKI67 is located 
upstream of the transcription start site. Several 
studies have shown that the 5' flanking region of the 
gene has promoter activity via reporter gene 
expression assays and deletion analysis (Zambon, 
2010; Pei et al., 2012). The promoter region was 
shown to contain a TATA-less, GC rich region with 
several putative Sp1 binding sites and two 
evolutionary conserved E2F transcription factor 
binding sites (Zambon, 2010; Pei et al., 2012). 
Gene: The gene consists of 15 exons and 14 
introns. The first exon and a part of the second form 
the 5' Untranslated Region (5' UTR) of the mRNA 
transcript (Duchrow et al., 1996; Schlüter et al., 
1993).  
 
The local order of genes around MKI67. The MKI67 gene is surrounded by the genes CLRN3 (clarin 3), PTPRE (protein 
tyrosine phospatase receptor type E), MGMT (O-6-methylguanine-DNA methyltransferase). 
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MKI67 gene structure. The UTRs are coloured green and the coding regions red. The introns are coloured yellow. MKI67 
consists of 15 exons of which the first and a part of the second exon form the 5' UTR. The 3' UTR is formed from a major part of 
exon 15, which contains only a small coding region. The table at the bottom of the figure shows the length of exons, coding 
regions and introns according to the information provided by the NM_002417.4 NCBI reference sequence. 
 
The second exon contains the start codon (Schlüter 
et al., 1993), with the open reading frame extending 
to the 15th exon, which consists of a short coding 
sequences, the stop codon and the 3' UTR 
(Duchrow et al., 1996; Schlüter et al., 1993). 
The 1080 bp 7th exon is not present in the 
alternatively spliced "short type" mRNA transcript. 
The 6845 bp 13th exon contains the characteristic 
sixteen homologous "Ki67 repeats", each of them 
having length of 366 bp. Within Ki67 repeats there 
is a highly conserved new motif of 66 bp named the 
"Ki67 motif" (Schlüter et al., 1993). 
The introns, vary in size from 87 to 3561 bp. Three 
introns contain recognized homologue copies of 
"Alu-repeats". All the intron-exon transitions 
contain a potential branch site with the exception of 
the introns flanking exon 7 where there is not any 
donor-acceptor splicing signal (Durchow et al., 
1996). 
Transcription 
There are two mRNA splice variants of MKI67, 
that are shown to be processed through translation. 
These two mRNA variants are named as "long 
type" and "short type" since they differ only by the 
presence or absence of exon 7 (Schlüter et al., 
1993). 
The "long type" mRNA splice variant consists of 15 
exons and its total annotated spliced exon length is 
12497 bp (NCBI Reference Sequence: 
NM_002417.4). The "short type" mRNA splice 
variant consists of 14 exons lacking the 7th exon 
and its annotated spliced exon length is 11417 bp 
(NCBI Reference Sequence: NM_001145966.1). 
Pseudogene 
There is one related pseudogene of MKI67 on 
chromosome X, named MKI67P1 (marker of 
proliferation Ki-67 pseudogene 1) with Gene ID 
100271918. The MKI67P1 pseudogene is located 
on chromosomal locus Xp11. It has 1449 bp length 
and NCBI Reference Sequence: NG_011647.1. 
Protein 
Note 
The MKI67 protein can be found in two complete 
isoforms, the heavy isoform produced from the 
"long type" mRNA and the light isoform translated 
from the "short type" mRNA, lacking the 7th exon. 
The heavy isoform, referred as Antigen Ki67 
isoform 1 with NCBI Reference Sequence: 
NP_002408.3, consists of 3256 aminoacids (aa) and 
weights approximately 395 kDa. The light isoform, 
referred as Antigen Ki67 isoform 2 with NCBI 
Reference Sequence: NP_001139438.1, consists of 
2896 aa lacking the 360 aa encoded by exon 7 and 
has a molecular weight of about 345 kDa. 
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The MKI67 mRNA and protein. The two types of mRNA transcripts, shown to be translated to protein, are depicted in the first 
part of the figure. The long type mRNA differs from the short type by the presence of the 7th exon which is alternatively spliced in 
the short type. The UTRs are coloured green and the coding regions red. At the second part of the figure, it is depicted the 
protein product of the long type mRNA which contains all the putative domains of this protein. The major protein domains are the 
FHA domain coloured red, the PPI binding site coloured purple, the Ki67 repeats coloured yellow and the ATP/ GTP binding site 
motif A-P loop coloured blue. There are other putative functional regions within these major domains, which are highlighted in 
different colours. 
 
Description 
Starting from the N-terminus: 
Major domains: 
- Forkhead associated domain (FHA): 8-98 aa. 
This domain is characterized as a modular 
phosphopeptide recognition domain with specificity 
to phosphothreonine containing sequences 
(Hammet et al., 2003; Durocher et al., 1999). The 
MKI67 FHA domain is shown to lie at the N-
terminus of the protein. According to computer 
alignment, the core domain is found within 27-76 
amino acids but the functional domain is believed 
to expand from 8 to 98 residue. So far, two proteins 
have been identified to interact with MKI67 FHA 
domain, the hNIFK (human nucleolar protein 
interacting with the FHA domain of pKi-67) and 
the Hklp2 (human kinesin-like protein 2). 
- Protein phosphatase 1 binding site: 502-563 aa. 
The Protein Phosphatase 1 (PPI) is a Ser/Thr 
phosphatase which belongs to the PPP family of 
phosphatases, and it is believed to dephosphorylate 
its substrates in large complexes consisting of 
regulatory as well as target proteins (Moorhead et 
al., 2008). In MKI67 protein there is a docking site 
of PPI at the N-terminal part of the protein within 
residues 502 to 563. 
- Ki67 Repeats: 
1) 1002-1113 aa, 2) 1124-1235 aa, 3) 1246-1357  
aa, 4) 1368-1478 aa, 5) 1489-1599 aa, 6) 1610-
1721 aa, 7) 1732-1843 aa, 8) 1854-1965 aa, 9) 
1976-2087 aa, 10) 2098-2204 aa, 11) 2216-2327 aa, 
12) 2337-2448 aa, 13) 2459-2570 aa, 14) 2582-
2690 aa, 15) 2701-2806 aa, 16) 2820-2929 aa. 
The Ki67 repeat is a cluster of 122 residues 
repeated 16 times within the 13th exon of the 
molecule with identity ranging from 43 to 62% to 
the consensus sequence.  
Within the Ki67 repeat there is a highly conserved 
motif of 22 amino acids named "the Ki67 motif" 
which has 72-100% identity to the consensus 
sequence and includes the F-K-E-L epitope 
recognized by the prototype Ki67 antibody 
(Schlüter et al., 1993).  
So far, their function remains an enigma. 
- ATP/ GTP binding site motif A-P loop: 3034-
3041 aa. 
A-P-R-A-R-G-K-S 
At the C-terminus of the protein there is a sequence 
resembling the predictive nucleotide binding site of 
Walker A motif.  
This well-known motif is a nucleotide binding fold 
recognized by Walker et al. (1982) and it is found 
in many nucleotide binding proteins. 
Minor domains: 
- PEST sequences: 
The cDNA sequences show 40 weak and 10 strong 
PEST sites.  
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These sites are named as PEST due to the fact that 
they are rich in proline, glutamic acid (E), serine 
and threonine and to a lesser extent aspartic acid. 
They are found in several proteins with diverse 
functions such as key metabolic enzymes, 
transcription factors, protein kinases, phosphatases 
and cyclins. The regulation of proteins based on 
PEST sequences is characterized by strict 
expression, high susceptibility to proteolysis and 
short half-life, especially in those proteins 
participating in cell cycle and mitosis regulation. In 
MKI67 protein, the 10 strongest PEST sequences 
are located within exon 13, surrounding the 
conserved cysteine residues at position 8 of the 
Ki67 repeats (Ross and Hall, 1995). PEST 
sequences seem to be functional in the MKI67 
protein, based on its biological behavior with 
susceptibility to proteases, short half-life and rapid 
loss of the protein after mitosis (Ross and Hall, 
1995; Schlüter et al., 1993). 
- Putative Monopartite Nuclear Targeting 
Sequences: 502-505 and 687-690 aa. 
The MKI67 protein has two putative monopartite 
nuclear targeting sequences at the N-terminal part 
of the protein, which could function as nuclear 
localization signals (NLS) through the classical 
importin a/b nuclear import mechanism. 
- Putative Bipartite Nuclear Targeting Sequences: 
1) 536-550 aa, 2) 1516-1530 aa, 3) 2244-2258 aa, 
4) 2365-2379 aa, 5) 2651-2665 aa, 6) 2890-2904 
aa, 7) 2997-3011 aa, 8) 3141-3155 aa. 
There are other classical nuclear targeting 
sequences within this molecule, which could 
mediate nuclear localization with importin a/b 
pathway as well. These bipartite sequences are 
characterized by two clusters of basic residues 
separated by a 10 to 12 aa linker that is tolerant to 
residue substitution (Kosugi et al., 2009). 
- Post-translational modifications: 
The predicted post-translational modifications of 
MKI67 protein comprise 19 N-myristoylation, 3 
amidation and over 200 phosphorylation sites (143 
PKC, 89 casein kinase II, 2 tyrosine kinase sites 
and 8 consensus sites for Cdc2 kinase) (Schlüter et 
al., 1993). 
- MKI67 protein interactions: 
The MKI67 protein has been found to interact 
directly with four proteins. The HP1 proteins, 
which are small non-histone chromosomal proteins 
found in several chromatin complexes, interact with 
its C-terminal region (Kametaka et al., 2002). The 
Hklp2, a kinesin-like motor, interacts with the N-
terminal FHA domain of MKI67 protein (Sueishi et 
al., 2000). Another protein shown to interact with 
the N-terminal FHA domain of MKI67 protein is a 
putative RNA-binding protein with length of 293 
residues, named hNIFK (Takagi et al., 2001). 
MKI67 protein was found to be a candidate protein 
for interacting with the HiNF-P transcription factor 
in a yeast two-hybrid screen (Miele et al., 2007). 
Finally, several studies have shown that MKI67 
protein interacts with DNA and more specifically 
with the heterochromatin (Kreitz et al., 2000; 
Bridger et al., 1998). 
Expression 
The expression profile of MKI67 is much more 
related to the proliferating state of a cell rather than 
to the histological background of that cell. Through 
immunostaining experiments Gerdes et al. (1983) 
showed that this gene is present in proliferating 
normal cells such as germinal centers of cortical 
follicles, cortical thymocytes, neck cells of 
gastrointestinal mucosa and other cell lines but 
absent in resting differentiated cells such as 
lymphocytes, monocytes, hepatocytes, renal, brain, 
or parietal cells and many others.  
A very important finding was that the expression of 
MKI67 was triggered in differentiated cells after 
proliferative stimulation and disappeared after 
differentiation of proliferating cells (Gerdes et al., 
1983).  
During cell cycle this gene is always detectable 
through G1, S, G2 and M phase at continuously 
proliferating cells but totally absent in resting cells 
at G0 phase (Gerdes et al., 1984). 
Localisation 
Distribution of MKI67 protein during cell cycle: 
1. Interphase: 
a. Early G1 phase: Accumulates in several foci 
within the nucleoplasm (Gerdes et al., 1983; Kill, 
1996). 
b. Late G1, S, G2 phase: Localizes predominantly 
within nucleoli at the dense fibrillar component but 
also there is diffuse nucleoplasmic staining (Gerdes 
et al., 1983; Kill, 1996). 
2. Mitosis: Coats chromosome surface (Gerdes et 
al., 1983). 
a. Metaphase: a reticulate but uniform network of 
fibrils around chromosomes, at the 
perichromosomal layer (Ross and Hall, 1995). 
b. Anaphase: a reticulate more granular network of 
fibrils around chromosomes with the highest 
density of staining (Ross and Hall, 1995). 
c. Telophase: the staining moves from the 
perichromosomal layer and becomes speckled at the 
nucleoplasm and subsequently concentrates at the 
newly reformed nucleoli (Ross and Hall, 1995). 
Function 
The function of MKI67 protein during cell cycle is 
still unknown. However, experiments with anti-
sense oligonucleotides and antibodies against 
MKI67 revealed a decreased rate of cell division, 
indicating the important role of this protein in cell 
cycle (Schlüter et al., 1993; Starborg et al., 1996).  
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More details for MKI67 function are unavailable, 
although there are some assumptions based on 
localization and protein-protein interactions 
experimental data. 
Models: 
1. Nucleolar localization of MKI67 protein is 
believed to be related to: 
a. Structural modulation of the nucleolus in order to 
enhance the high rates of ribosomal synthesis 
during cell proliferation, since its expression is 
related to high rates of protein synthesis (Plaat et 
al., 1999; Scholzen et al., 2002). 
b. Sequestration of MKI67 protein within nucleoli 
until the mitosis starts again. During mitosis the 
nucleolar structures are dispersed and the MKI67 
protein is free to interact with nuclear components 
(Scholzen et al., 2002). 
2. Localization of MKI67 to the surfaces of 
chromosomes during mitosis (prometaphase to 
anaphase) is believed to be related to: 
a. Protection of chromosomal surface during 
mitosis (Verheijen et al., 1989; Yasuda and Maul, 
1990). 
3. DNA interaction: 
a. It was believed that the central part of the MKI67 
protein and especially the "Ki67 repeat" region has 
the ability to bind DNA through its Thr-Pro-X-X 
motif (Schlüter et al., 1993). 
b. The LR domain has the ability to bind DNA in 
order to compact chromatin (Kametaka et al., 
2002). 
Homology 
The MKI67 gene has homologous genes in several 
organisms such as chimpanzee, rhesus monkey, 
dog, cattle, mouse and rat.  
Additionally, through genome annotation studies, 
53 other organisms have been found to carry an 
MKI67 orthologue. However, the most interesting 
case is a similar but not homologous gene, found in 
the long-nosed rat Kangaroo, named chmadrin 
(Takagi et al., 1999). The chmadrin protein has 
primary structural similarities with the MKI67 
protein. The N-terminal region of the chmadrin 
protein has a nucleotide binding motif which is 
similar to a putative one found in MKI67 at the C-
terminal region (Takagi et al., 1999). The central 
region of chmadrin contains a repetitive sequence 
domain, named the "chmadrin repeat domain" 
which resembles the "Ki67 repeat domain" (Takagi 
et al., 1999). Finally, both of these proteins have 
LR domains with conserved functionality but 
different amino acid sequence (Takagi et al., 1999). 
Mutations 
Note 
MKI67 is used as a tumor proliferation marker with 
an unknown function. The contribution of this gene 
in tumor development is unknown. In 2003, Buban 
et al. found eight different point mutations in four 
tumor cell lines (HeLa, CXF94, SW480, A549) 
indicating that MKI67 might provide a genetic 
background in tumor development. These mutations 
include a deletion in position 1496 resulting in a 
truncated product, a base exchange silent mutation 
in position 433 (A433T) and six other exchange 
mutations resulting in residue changes (Buban et 
al., 2004). 
Implicated in 
Several cancers 
Note 
Although the MKI67 gene is not associated with 
any type of human cancer as a causative factor, it is 
implicated in many of them as a prognostic factor 
based on the expression profile of this gene at 
tumor cells. Additionally, a new application of 
MKI67 expression is the implication in diagnosis of 
certain diseases such as lymphoma. The prognostic 
value of MKI67 expression in malignancy was 
categorized by Brown and Gatter (2002) into three 
classes: 
1. Group of malignancies where >75% of the 
studies shown significant prognostic value: breast 
cancer, soft tissue tumors, lung cancer, astrocytoma 
and meningioma. 
2. Group of malignancies where 25-75% of the 
studies shown significant prognostic value: cervical 
cancer, prostate cancer. 
3. Group of malignancies where <25% of the 
studies shown significant prognostic value: 
colorectal cancer. 
Breast cancer 
Note 
In breast cancer, most of the studies show 
significant correlation between MKI67 expression 
in tumor cells and clinical outcomes both in 
univariate and multivariate analysis (Brown and 
Gatter, 2002; Kontzoglou et al., 2013). The 
prognostic value of MKI67 expression in breast 
cancer is comprised in the following conclusions: 
1. MKI67 expression is associated with common 
histopathological parameters and the strongest 
correlation is established with tumor grading 
(Inwald et al., 2013). 
2. MKI67 expression is an independent prognostic 
parameter of overall and disease-free survival 
(Inwald et al., 2013). 
3. MKI67 expression is associated with earlier 
central nervous system metastases (Ishihara et al., 
2013). 
4. In triple negative breast cancer (TNBC) MKI67 
expression could be used to classify TNBC into two 
subtypes with different prognosis (Keam et al., 
2011). 
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5. In node-negative breast cancer, which is treated 
with surgery and subsequent radiation but not with 
adjuvant systemic therapy, MKI67 expression and 
hormone receptor status is a significant prognostic 
parameter of survival (Pathmanathan et al., 2014). 
6. The expression of MKI67 gene after neoadjuvant 
chemotherapy is prognostic of disease relapse and 
death (von Minckwitz et al., 2013; Tanei et al., 
2011). 
7. The prognostic value of MKI67 expression is 
available in samples of breast tumors acquired via 
fine needle aspirate with accuracy comparable to 
histological evaluation (Konofaos et al., 2013). 
8. Breast cancer patients with Grade 3 tumors 
positive for MS110, Lys27H3, VIM (vimentin) and 
MKI67 expression are at high risk of carrying 
BRCA1 mutations and therefore could be screened 
for such mutations (Hassanein et al., 2013). 
Additionally, another diagnostic use of MKI67 
expression in breast cancer addresses two specific 
subtypes of this malignancy: 
1. In Phyllodes tymor the expression of MKI67 and 
TP53 mRNA is associated with the grade of this 
tumor and could help in distinguishing the benign 
from the malignant form (Kucuk et al., 2013). 
2. The expression profile of the estrogen receptor, 
ERBB2 (c-erbB2) and MKI67 mRNA could help in 
distinguishing between Toker cells, which are 
normal components of nipple epidermis, and cells 
of Paget's disease (Park and Suh, 2009). 
Endometrial cancer 
Note 
Although in endometrial cancer MKI67 expression 
is used as a proliferation marker associated with 
specific characteristics of this tumor, there is not yet 
any validated prognostic or diagnostic connection 
as there is for breast cancer. More specifically: 
1. High MKI67 expression is associated with 
endometrial cancer and the overexpression of 
MKI67 and TP53 genes indicates a more malignant 
phenotype with poor differentiation of the tumor 
cells (Markova et al., 2010). 
2. High MKI67 expression is correlated with poorly 
differentiated carcinomas, invasion of the 
myometrium and stage III tumor (Stoian et al., 
2011). There is also a significant correlation with 
the degree of differentiation, the stage of tumor and 
vascular invasion (Stoian et al., 2011). 
3. MKI67 expression is higher in high-grade 
endometrial carcinomas and complete negative in 
atrophic endometrium (Mourtzikou et al., 2012). 
4. High MKI67 expression correlates with 
morphologic features of aggressiveness and high 
grade of endometrial cancer (Konstantinos et al., 
2013). 
5. Although previous studies associated MKI67 
expression with survival, recent ones correlate 
survival with estrogen and progesterone receptors 
expression rather than MKI67 gene (Li et al., 2014; 
Salvesen et al., 1999; Gassel et al., 1998). 
Cervical cancer 
Note 
In cervical cancer MKI67 expression is used as a 
proliferation index marker of malignant cells, 
associated with specific characteristics of the tumor 
but not as a prognostic factor of survival or disease 
relapse.  
Additionally, it is suggested that under certain 
circumstances MKI67 expression could be used in 
low-grade lesion triage for referral colposcopy. 
More specifically: 
1. There is no significant correlation between 
MKI67 expression and classical prognostic factors 
(Ancuta et al., 2009). 
2. MKI67 and CDKN2A (P16) gene is expressed in 
cervical intraepithelial neoplasia (CIN) and the 
intensity of positive expression is significantly 
correlated with CIN grade (Shi et al., 2007). In 
another study these two markers were shown to 
increase linearly from control cases to more 
dysplastic lesion to squamous cell carcinoma (Gatta 
et al., 2011). This indicates that CDKN2A and 
MKI67 gene could be useful markers in diagnosis 
and staging of CIN lesions (Shi et al., 2007). 
3. Expression of CDKN2A, MKI67 gene and 
ProxEX C (a cocktail of monoclonal antibodies 
against proteins associated with aberrant S phase 
cell cycle induction) are most associated with the 
severity of cervical dysplasia and related to HPV-16 
infection (Conesa-Zamora et al., 2009). 
4. MKI67 expression is enhanced in high grade 
CIN lesions and cervical squamous cell carcinoma 
(Looi et al., 2008). TP63 and MKI67 expression is 
correlated better with cancer progress than TP53 
expression (Vasilescu et al., 2009). 
5. CDKN2A/MKI67 expression increases 
according to histologic severity and could be used 
to predict high-grade lesion better than HPV DNA 
testing since it is more accurate in patients with 
atypical squamous cells (Koo et al., 2013). 
Additionally, they could be used for low-grade 
squamous intraepithelial lesions triage better than 
HPV DNA testing and reduce referral colposcopy 
to almost the half by detecting the more severe 
cases of CIN3 (Wentzensen et al., 2012). 
Ovarian cancer 
Note 
In ovarian cancer MKI67 expression is associated 
with several histopathological characteristics of the 
malignancy and in some subtypes with the overall 
survival. However, more studies are needed in order 
to validate such correlations. More specifically: 
1. PIK3CA amplifications and MKI67 expression 
are strong predictors of an early tumor-associated 
death (Woenckhaus et al., 2007). 
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2. The combined evaluation of CDKN1B 
(P27KIP1) and MKI67 expression in ovarian 
carcinomas is an independent and more accurate 
prognostic marker of overall survival than each 
marker alone (Korkolopoulou et al., 2002). 
3. In stage III ovarian carcinomas, MKI67 
expression is an independent prognostic marker 
where high expression of this gene is significantly 
associated with shorter survival (Khouja et al., 
2007). 
4. The expression of MKI67 gene is higher in 
malignant ovarian tissues than control ones and 
within the malignant tissues it is enhanced in low 
differential carcinoma and stage III-IV (Wang et al., 
2010b). 
5. The expression of MKI67 gene is higher in 
primary ovarian tumors than in metastatic cells 
(Wang et al., 2010b). 
6. The high-grade ovarian carcinomas have 
significantly higher expression of MKI67 gene than 
the low-grade, but there is little correlation between 
this expression and overall or disease-free survival 
(Shen et al., 2011). 
7. The MKI67 expression is associated with higher 
cancer stage and histological grade and a worse 
outcome for patients (Heeran et al., 2013). 
8. The MKI67 expression was found to be 
associated with poorer overall survival in ovarian 
cancer patients (Kucukgoz Gulec et al., 2014). 
Vulvar cancer 
Note 
The vulvar carcinomas, mainly represented by 
squamous cell carcinoma (SCC) and non-invasive 
lesion of vulvar intraepithelial neoplasias (VINs), 
are associated with MKI67 expression in several 
studies.  
The general idea is that the expression of this gene 
is associated with dysplastic lesions and it is more 
intense in more malignant lesions. More 
specifically: 
1. The expression of MKI67 and CDKN2A are 
statistically positively related with HPV-associated 
dysplastic lesions (Gincheva et al., 2009). 
2. There is an increase in MKI67 and TOP2A 
(topoisomerase IIa) expression in VIN lesions and 
SCC comparing to normal vulvar epithelia, 
indicating these two genes as markers of 
proliferation in vulvar epithelial tissues (Brustmann 
and Naude, 2002). 
3. In differentiated VIN lesions the MKI67 
expression is confined in the basal and parabasal 
layers.  
However, in usual VIN lesions associated with 
high-risk HPV virus infection, MKI67 is highly 
expressed (Hoevenaars et al., 2008; Ding et al., 
2012). 
Bladder cancer 
Note 
In bladder cancer MKI67 expression is examined in 
several studies classifying this gene as a common 
marker used in diagnosis and staging of this 
malignancy. The expression of this gene is 
correlated with the grade and the stage of the 
malignancy and it is higher in females (Wang et al., 
2013). 
Gliomas: astrocytomas, 
oligodendrogliomas 
Note 
In these brain tumors the MKI67 gene has great 
potential as a marker of cell proliferation, survival, 
therapy response and even discrimination between 
subtypes of gliomas. High expression of this gene is 
related with shorter overall survival of patients (Liu 
et al., 2013b). Additionally, MKI67 expression was 
shown to be correlated with survival of patients 
with a specific subtype of gliomas in univariable 
analysis, indicating the prognostic potential of this 
gene in glioma tumors (Preusser et al., 2012). The 
MKI67 expression could also be associated with 
post-treatment results, such as in adjuvant 
radiotherapy of gliomas where high expression is 
correlated with worse response to the therapy 
(Horbinski et al., 2012). Another interesting study 
showed that MKI67 might have differential 
expression between subtypes of gliomas indicating 
a role in diagnosis of these subtypes in accordance 
to other promising molecular markers (Huang et al., 
2011). 
Meningiomas 
Note 
MKI67 is believed to have some influence in 
meningioma development and progression since 
there is significant correlation between its 
expression and tumor grade, certain subtypes, 
tumor recurrence and size (Pavelin et al., 2013; 
Wang et al., 2010a). Another interesting correlation 
was proposed by Uzum and Ataoglu (2008) in 
which the tumor grade is the most important 
prognostic factor of meningiomas, which in turn is 
significantly correlated with MKI67 expression. 
Terzi et al. (2008) proposed that MKI67 and TP53 
expression could be useful additional markers for 
grade classification in borderline cases. 
Pituitary adenomas 
Note 
The MKI67 expression is correlated with neoplasm 
recurrence and visual field defect (Paek et al., 
2005). Additionally, it is believed to be an 
independent predictor of pituitary adenomas' 
progression after surgery (Gejman et al., 2008).  
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In general MKI67 is a useful marker in predicting 
tumor recurrence or invasiveness in accordance to 
other factors (de Aguiar et al., 2010). 
Gastric cancer 
Note 
In gastric cancer the relation of MKI67 with the 
characteristics of this malignancy are not well 
established. Expression of MKI67 and PCNA are 
correlated with high grade of gastric cancer 
(Czyzewska et al., 2004). The overexpression of 
TSPAN1 and MKI67 genes are negatively 
correlated with carcinoma differentiation (Chen et 
al., 2008). Additionally, MKI67 expression is 
shown to be related to tumor size (Giaginis et al., 
2011). 
Gastrointestinal stromal tumor 
Note 
MKI67 expression is higher in the malignant 
gastrointestinal stromal tumors than in benign ones, 
indicating a role in predicting malignant potential 
of GIST in accordance with other tumor markers 
such as TP53 and KIT (c-kit) (Aoyagi et al., 2009). 
Addditionally, MKI67 expression was correlated 
with GIST recurrence and patient survival (Belev et 
al., 2013; Liu et al., 2013a). 
Colorectal cancer 
Note 
In colorectal cancer, the MKI67 gene is associated 
with several characteristics of this malignancy. 
Additionally, there is a strong correlation of gene 
expression with the response of this cancer to 
potential therapeutic approaches. More specifically: 
1. MKI67 in addition to other tumor markers such 
as CD34, KRT19 (CK19), KRT20 (CK20) are 
highly expressed in colorectal cancer compared to 
normal tissues. Additionally, expression of CD34 
and MKI67 are significantly correlated with tumor 
stage, differentiation and low survival (Ma et al., 
2010). 
2. MKI67 and BMI1 overexpression in colorectal 
cancer is significantly related to tumorigenesis, 
metastasis and prognosis (Lin et al., 2008). 
3. MKI67 expression is a reliable marker for 
predicting metastatic potential of rectal carcinoid 
(Hotta et al., 2006). 
4. The expression of MKI67, PDPN (podoplanin) 
and cytokeratin are correlated with increased 
lympangiogenesis but not with poorer prognosis 
(Omachi et al., 2007). 
5. Decreased expression of MKI67, HIF1A and 
BCL2 markers were found after chemoradiotherapy 
of rectal cancer (Havelund et al., 2013). 
6. Rectal tumors with lower MKI67 expression 
were more sensitive to neoadjuvant therapy and the 
gene expression was decreased after the therapy 
(Jiang et al., 2008). 
7. High MKI67 expression in colon cancer is 
associated with better relapse-free survival in 
patients who underwent surgery and adjuvant 
chemotherapy (Fluge et al., 2009). 
8. MKI67 expression and the inflammation marker, 
C-reactive protein are correlated with poorer 
survival in patients undergoing surgery for 
colorectal cancer (Canna et al., 2008). 
Lung cancer 
Note 
The MKI67 gene is not a validated prognostic 
marker in non-small cell lung cancer and more 
studies with standardized methodology are required 
to elucidate the role of this marker in this lung 
cancer subtype (Jakobsen and Sorensen, 2013). 
Lymphoma 
Note 
In lymphoma malignancies, MKI67 is considered 
as a powerful tool in distinguishing benign from 
malignant cases (Bryant et al., 2006). Additionally, 
MKI67 can be used as a prognostic factor of 
survival, with highly expressing tumors being 
correlated with worse overall survival (Kim et al., 
2007). However, in specific subtypes such as 
diffuse large B-cell lymphoma low expression of 
MKI67 is an adverse prognostic factor (Hasselblom 
et al., 2008). Another use of MKI67 expression is 
the evaluation of prognosis after therapy in specific 
lymphoma subtypes (Determann et al., 2008). 
Neuroendocrine tumors 
Note 
In neuroendocrine tumors, MKI67 expression is the 
sole strong independent risk factor for poor 
outcome and it is considered as predictor marker of 
disease progression and it is significantly associated 
with patients' overall survival (Panzuto et al., 2012). 
The use of MKI67 expression is believed to be a 
better prognostic marker than mitotic count in these 
malignancies (Khan et al., 2013). This gene is 
incorporated in the grading of neuroendocrine 
neoplasms into two major categories: a) well 
differentiated neuroendocrine tumors (grade 1 and 
2) and b) poorly differentiated endocrine 
carcinomas (grade 3) (Fung et al., 2013). In ileal 
well-differentiated neuroendocrine tumors, MKI67 
predicts the progression-free survival (Dhall et al., 
2012). However, a differentiation about the 
prognostic value of this gene is reported for the 
small cell lung patients where it has no prognostic 
value (Erler et al., 2011). 
Thyroid cancer 
Note 
In thyroid carcinomas, MKI67 and TP53 are 
expressed with increasing frequency in progressed 
stages of this cancer (Saltman et al., 2006).  
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MKI67 expression and mutational analysis of RET 
gene could be used as prognostic factors of more 
aggressive medullary thyroid carcinoma (Mian et 
al., 2011). MKI67 expression, LGALS3 (Galectin-
3) and PTTG1 (pituitary tumor transforming 1) 
genes could be used not only to distinguish benign 
from malignant tumors but also to differentiate 
follicular carcinoma from papillary one (Cui et al., 
2012). 
Other cancers 
Note 
Basal cell carcinoma, cutaneous pilar leiomyoma, 
leiomyosarcoma, embryonal tumors, gallbladder 
carcinoma, hypopharyngeal-squamous cell 
carcinoma, squamous cell carcinoma of larynx, 
malignant fibrous histiocytoma, parathyroid cancer, 
hepatocellular carcinoma, prostate cancer, penile 
carcinoma, retinoblastoma and salivary gland 
tumors are some of the malignancies in which 
MKI67 expression is considered as proliferation, 
stage, grade or survival marker. However, more 
sophisticated studies are needed in order to 
elucidate the exact correlation of this gene with 
these tumors. 
Other non-malignant diseases 
Note 
MKI67 is evaluated in several other not malignant 
diseases, mostly as a proliferation marker, such as 
hemimegalencephaly, eosinophilic esophagitis, 
hepatitis, Reinke's edema, problems in placental 
development, psoriasis, Barret's esophagus, 
endometriosis, multiple sclerosis, hemangioma, 
myocardial infarction, Alzheimer disease, 
Langerhans cell histiocytosis and endometrial 
polyps. 
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